Advertisement
Science
ChinaScience

US lawmakers killed a proposal targeting science efforts with China, and did this instead

US researchers and industry experts warn that even the revised version may have unintended consequences

2-MIN READ2-MIN
11
Listen
A US defence bill, now awaiting President Donald Trump’s signature, includes new restrictions aimed at the medical industry and supply chains, blocking federal funds from going to biotechnology companies linked to so-called adversaries. Photo: Reuters
Ling Xinin Ohio
The US Congress passed its annual defence bill on Wednesday, easing concerns among researchers by dropping a controversial proposal targeting US-China scientific collaboration, even as it imposed new restrictions on Chinese biotechnology companies.

The SAFE (Securing American Funding and Expertise from Adversarial Research Exploitation) Research Act would have denied federal funding to any US researcher working with scientists from China and several other countries, but it did not make it into the US$901 billion National Defence Authorisation Act for the 2026 financial year.

The proposal, introduced by Michigan Republican Representative John Moolenaar, was widely criticised by the US research community, including senior academics and major scientific organisations.

‘We have a deal’: Trump claims breakthrough after ‘12 out of 10’ talks with Xi Jinping

Lin Haifan, a cell biologist at Yale University, told Science magazine that such a measure could “accelerate the breakdown of the people-to-people trust” that was key to scientific collaboration.

“Without this kind of positive energy, the US and China will become more and more polarised and eventually become each other’s enemy,” he said last month.

Select Voice
Select Speed
1x
AI-generated voice